Cargando…

Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population

BACKGROUND: Cancer-related cognitive impairment is a common and potentially debilitating symptom experienced by patients with non-central nervous system (CNS) cancers, with negative impact on their quality of life. The Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 (FACT-Cog-v3...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Ana F., Santos, Isabel M., Fernandes, Sofia, Bem-Haja, Pedro, Torres, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748889/
https://www.ncbi.nlm.nih.gov/pubmed/36517827
http://dx.doi.org/10.1186/s40359-022-01018-w
_version_ 1784849924109631488
author Oliveira, Ana F.
Santos, Isabel M.
Fernandes, Sofia
Bem-Haja, Pedro
Torres, Ana
author_facet Oliveira, Ana F.
Santos, Isabel M.
Fernandes, Sofia
Bem-Haja, Pedro
Torres, Ana
author_sort Oliveira, Ana F.
collection PubMed
description BACKGROUND: Cancer-related cognitive impairment is a common and potentially debilitating symptom experienced by patients with non-central nervous system (CNS) cancers, with negative impact on their quality of life. The Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 (FACT-Cog-v3) is the most extensively used instrument specifically developed to evaluate cognitive complaints in adult cancer patients. Nevertheless, this self-report measure is not yet validated for the Portuguese population. Therefore, the purpose of this study was to evaluate the psychometric properties of the FACT-Cog-v3 among patients with non-CNS cancers in Portugal. METHODS: The validation study was conducted based on a convenience sample of 281 patients with non-CNS cancers, aged between 18 and 65 years, recruited online. A confirmatory factor analysis (CFA) was used to test the factor structure of the Portuguese FACT-Cog-v3 version; internal consistency analysis was also conducted. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30–version 3) and the Hospital Anxiety and Depression Scale (HADS) were also used to test the concurrent, convergent, and discriminant validity of the scale. RESULTS: CFA supported a four-factor model with good fix indexes and internal consistencies: perceived cognitive impairments (α = 0.97), comments from others (α = 0.92), perceived cognitive abilities (α = 0.93), and impact on quality of life (α = 0.92). Concurrent, convergent, and discriminant validities were confirmed. Moderate and strong correlations were found between the FACT-Cog-v3 subscales and the QLQ-C30 cognitive functioning subscale. Good convergent validity, with moderate correlations, was found between the FACT-Cog-v3 subscales and the HADS-A, HADS-D, and QLQ-C30 fatigue, sleep disturbance, and global health status subscales. Acceptable discriminant validity, with weak and moderate correlations, was demonstrated between the FACT-Cog-v3 subscales and the QLQ-C30 pain and nausea/vomiting subscales. CONCLUSIONS: The Portuguese FACT-Cog-v3 version can be considered a reliable and valid measure to assess cognitive concerns of patients with non-CNS cancers, with relevance for research and clinical practice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40359-022-01018-w.
format Online
Article
Text
id pubmed-9748889
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97488892022-12-14 Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population Oliveira, Ana F. Santos, Isabel M. Fernandes, Sofia Bem-Haja, Pedro Torres, Ana BMC Psychol Research BACKGROUND: Cancer-related cognitive impairment is a common and potentially debilitating symptom experienced by patients with non-central nervous system (CNS) cancers, with negative impact on their quality of life. The Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 (FACT-Cog-v3) is the most extensively used instrument specifically developed to evaluate cognitive complaints in adult cancer patients. Nevertheless, this self-report measure is not yet validated for the Portuguese population. Therefore, the purpose of this study was to evaluate the psychometric properties of the FACT-Cog-v3 among patients with non-CNS cancers in Portugal. METHODS: The validation study was conducted based on a convenience sample of 281 patients with non-CNS cancers, aged between 18 and 65 years, recruited online. A confirmatory factor analysis (CFA) was used to test the factor structure of the Portuguese FACT-Cog-v3 version; internal consistency analysis was also conducted. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30–version 3) and the Hospital Anxiety and Depression Scale (HADS) were also used to test the concurrent, convergent, and discriminant validity of the scale. RESULTS: CFA supported a four-factor model with good fix indexes and internal consistencies: perceived cognitive impairments (α = 0.97), comments from others (α = 0.92), perceived cognitive abilities (α = 0.93), and impact on quality of life (α = 0.92). Concurrent, convergent, and discriminant validities were confirmed. Moderate and strong correlations were found between the FACT-Cog-v3 subscales and the QLQ-C30 cognitive functioning subscale. Good convergent validity, with moderate correlations, was found between the FACT-Cog-v3 subscales and the HADS-A, HADS-D, and QLQ-C30 fatigue, sleep disturbance, and global health status subscales. Acceptable discriminant validity, with weak and moderate correlations, was demonstrated between the FACT-Cog-v3 subscales and the QLQ-C30 pain and nausea/vomiting subscales. CONCLUSIONS: The Portuguese FACT-Cog-v3 version can be considered a reliable and valid measure to assess cognitive concerns of patients with non-CNS cancers, with relevance for research and clinical practice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40359-022-01018-w. BioMed Central 2022-12-14 /pmc/articles/PMC9748889/ /pubmed/36517827 http://dx.doi.org/10.1186/s40359-022-01018-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Oliveira, Ana F.
Santos, Isabel M.
Fernandes, Sofia
Bem-Haja, Pedro
Torres, Ana
Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population
title Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population
title_full Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population
title_fullStr Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population
title_full_unstemmed Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population
title_short Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population
title_sort validation study of the functional assessment of cancer therapy-cognitive function-version 3 for the portuguese population
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748889/
https://www.ncbi.nlm.nih.gov/pubmed/36517827
http://dx.doi.org/10.1186/s40359-022-01018-w
work_keys_str_mv AT oliveiraanaf validationstudyofthefunctionalassessmentofcancertherapycognitivefunctionversion3fortheportuguesepopulation
AT santosisabelm validationstudyofthefunctionalassessmentofcancertherapycognitivefunctionversion3fortheportuguesepopulation
AT fernandessofia validationstudyofthefunctionalassessmentofcancertherapycognitivefunctionversion3fortheportuguesepopulation
AT bemhajapedro validationstudyofthefunctionalassessmentofcancertherapycognitivefunctionversion3fortheportuguesepopulation
AT torresana validationstudyofthefunctionalassessmentofcancertherapycognitivefunctionversion3fortheportuguesepopulation